Author

Nayagam S

13 июля 2021 г.
Жизни спасены благодаря вакцинации против 10 патогенов в 112 странах в мире до COVID-19
Summary Background Vaccination is one of the most effective public health interventions. We investigate the impact of vaccination activities for Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae, and yellow fever over the years 2000-2030 across 112 countries. Methods Twenty-one mathematical models estimated disease burden using standardised demographic and […]

Читать далее
Январь 30, 2021
Оценка воздействия вакцинации против десяти патогенов на здоровье в 98 странах с низким и средним доходом с 2000 по 2030 год: модельное исследование
Summary Background The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030. Methods 16 independent research groups provided model-based […]

Читать далее
10 августа 2020 г.
Моделирование инфицирования вирусом гепатита В и воздействия своевременной дозы вакцины при рождении: сравнение двух имитационных моделей
Summary Hepatitis B is a global epidemic that requires carefully orchestrated vaccination initiatives in geographical regions of medium to high endemicity to reach the World Health Organization’s elimination targets by 2030. This study compares two widely-used deterministic hepatitis B models—the Imperial HBV model and the CDA Foundation’s PRoGReSs—based on their predicted outcomes in four countries. […]

Читать далее
Январь 30, 2018
Обоснование инвестиций в борьбу с гепатитом В и С в Южной Африке: адаптация и инновации в анализе политики для расширения масштабов программ борьбы с болезнями
Summary Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have […]

Читать далее